RADIOLOGICAL OR NUCLEAR MEDICAL COUNTERMEASURE PRODUCT DEVELOPMENT SUPPORT (PDS)
Contract Opportunity Analysis
The National Institute of Allergy and Infectious Diseases within the National Institutes of Health is seeking a contractor to support radiological or nuclear medical countermeasure product development, including biodosimetric approaches for assessing radiation exposure. The work will advance candidate medical countermeasures toward FDA approval or licensure for acute radiation syndrome and delayed effects of acute radiation exposure, with task areas covering administrative and technical support, animal model and NAMs development, efficacy testing, non-clinical studies, CMC support, and Phase I clinical studies. The effort is planned as a 7-year IDIQ beginning around July 1, 2027, and evaluation will emphasize the scientific approach, organizational capability, experience, and compliance with GLP, cGMP, and GCP, along with project management. The RFP is expected on or about June 2, 2026 through SAM.gov, and proposals must be submitted online through NIAID’s eCPS system with identical online and disk content; facsimile and email submissions are not acceptable.